跳至主要内容
临床试验/ITMCTR2200006029
ITMCTR2200006029
尚未招募
未知

A randomized controlled study of a combination of internal and external treatments for albumin paclitaxel-related peripheral neurotoxicity

Shanxi Institute of Traditional Chinese Medicine0 个研究点待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Peripheral neurotoxicity due to albumin paclitaxel
发起方
Shanxi Institute of Traditional Chinese Medicine
状态
尚未招募
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
3年前
研究类型
Interventional study
性别
All

研究者

发起方
Shanxi Institute of Traditional Chinese Medicine

入排标准

入选标准

  • ?Patients who have pathologically or cytologically confirmed lung cancer or breast cancer.
  • ?Patients' age 18\-80 years, regardless of gender.
  • ?Patients with a KPS score \= 60 and an expected survival of not less than 3 months.
  • ?Patients who have developed peripheral neurotoxicity after receiving albumin paclitaxel treatment.
  • ? no major visceral organ dysfunction and no cardiovascular or cerebrovascular complications.
  • ? Skin of all four limbs is intact.
  • ? Those who can understand the situation of this study, voluntarily accept the TCM treatment and voluntarily accept the questionnaire for good compliance.

排除标准

  • ?Patients with reduced platelets prone to bleeding.
  • ?Those who do not meet the above inclusion criteria.
  • ?Patients who have symptoms related to nerve compression due to brain metastases or who have peripheral nerve damage due to tumour compression.
  • ?Patients with other previous peripheral neuropathies, e.g. neurological diseases, orthopaedic related diseases, peripheral neuropathies due to circulatory disorders.
  • ? those with a history of allergy to drug exposure or the presence of skin lesions on the hands and feet (e.g. eczema).
  • ? Those who are unable to cooperate with treatment.
  • ?Women during pregnancy or breastfeeding.
  • ?Those currently or within 4 weeks participating in other clinical trials.
  • ?Allergic individuals who are susceptible to hypersensitivity to the drug.

结局指标

主要结局

未指定

相似试验